thalidomide has been researched along with Iron Overload in 6 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Iron Overload: An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We here describe a single-institution experience on 40 patients with myelodysplastic syndromes (MDS) consecutively treated with deferasirox at the dose of 10-30 mg/kg/day according to Consensus Guidelines on Iron Chelation Therapy, outside of clinical trials." | 7.78 | Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population. ( Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A, 2012) |
| "We here describe a single-institution experience on 40 patients with myelodysplastic syndromes (MDS) consecutively treated with deferasirox at the dose of 10-30 mg/kg/day according to Consensus Guidelines on Iron Chelation Therapy, outside of clinical trials." | 3.78 | Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population. ( Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A, 2012) |
| "We evaluated the risk factors for infection of 367 consecutive myeloma patients who underwent high-dose melphalan and autologous stem cell transplantation (ASCT)." | 2.72 | Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. ( Anaissie, EJ; Barlogie, B; Dong, L; Fassas, A; Grazziutti, ML; Miceli, MH; Thertulien, R; Van Rhee, F, 2006) |
| "Anemia and iron overload are complications in both diseases and are managed similar to lower risk MDS." | 2.52 | Refractory anemia with ring sideroblasts and RARS with thrombocytosis. ( Patnaik, MM; Tefferi, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patnaik, MM | 1 |
| Tefferi, A | 1 |
| Giagounidis, A | 1 |
| Nolte, F | 1 |
| Hofmann, WK | 1 |
| Breccia, M | 1 |
| Finsinger, P | 1 |
| Loglisci, G | 1 |
| Federico, V | 1 |
| Santopietro, M | 1 |
| Colafigli, G | 1 |
| Petrucci, L | 1 |
| Salaroli, A | 1 |
| Serrao, A | 1 |
| Latagliata, R | 1 |
| Alimena, G | 1 |
| Miceli, MH | 1 |
| Dong, L | 1 |
| Grazziutti, ML | 1 |
| Fassas, A | 1 |
| Thertulien, R | 1 |
| Van Rhee, F | 1 |
| Barlogie, B | 1 |
| Anaissie, EJ | 1 |
| Ohyashiki, K | 1 |
4 reviews available for thalidomide and Iron Overload
| Article | Year |
|---|---|
Refractory anemia with ring sideroblasts and RARS with thrombocytosis.
Topics: Anemia, Refractory; Anemia, Sideroblastic; Angiogenesis Inhibitors; Aspirin; Female; Humans; Iron Ov | 2015 |
Where Does Lenalidomide Fit in Non-del(5q) MDS?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 5; Com | 2015 |
[Current treatment options for myelodysplastic syndromes].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Blood Transfusion; Bone Marrow T | 2010 |
[Development trend in new therapeutic approaches for anemia].
Topics: Anemia; Benzoates; Clinical Trials as Topic; Darbepoetin alfa; Deferasirox; Erythropoietin; Hematini | 2008 |
1 trial available for thalidomide and Iron Overload
| Article | Year |
|---|---|
Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients.
Topics: Analysis of Variance; Angiogenesis Inhibitors; Female; Humans; Infections; Iron Overload; Male; Midd | 2006 |
1 other study available for thalidomide and Iron Overload
| Article | Year |
|---|---|
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Benzoates; Chelating Agents; Deferasir | 2012 |